Autopsy report · NCT01487174

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

“Kadmon has made a business decision to terminate the study due to slow enrollment. Note the decision to terminate the study was not related to safety issues”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 7 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Kadmon Corporation, LLC

Sponsor type

Industry

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

KD019; Erlotinib

Participants

8

Sites

2

Countries

United States

Trials that died the same way

• A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
  “Study has been terminated due to slow enrollment.” (71% match in meaning)
• Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs
  “Study terminated due to slow enrollment and change in strategy.” (70% match in meaning)
• Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
  “Study terminated due to slower than anticipated enrollment.” (70% match in meaning)
• Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
  “The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.” (69% match in meaning)
• Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting
  “The study was terminated on 02-Jun-2014 due to slow enrollment. The study was not terminated for reasons of either safety or efficacy.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.